Bruce Charles Neal
The University of Sydney
4 papers in the Anchorcite directory, published between 2016 and 2020, cited 34,785 times in total.
ORCID profileResearch topics
- Cardiovascular Health and Risk Factors · 2 papers
- Global Health and Epidemiology · 2 papers
- Diabetes Treatment and Management · 2 papers
- Chronic Kidney Disease and Diabetes · 2 papers
- Healthcare Systems and Public Health · 1 paper
- Heart Failure Treatment and Management · 1 paper
Frequent co-authors
- Ali H. Mokdad · 2 papers
- Marissa Bettay Reitsma · 2 papers
- Theo Vos · 2 papers
- Michael D Brauer · 2 papers
- Vlado Perkovic · 2 papers
- Kenneth W. Mahaffey · 2 papers
- Dick de Zeeuw · 2 papers
- Gerry R. Fowkes · 1 paper
Papers
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019Journal of the American College of Cardiology · 2020 · 12,352 citations
Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and…
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine · 2017 · 8,032 citations
Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The…
- Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015The Lancet · 2016 · 7,979 citations
BACKGROUND: The Global Burden of Diseases, Injuries, and Risk Factors Study 2015 provides an up-to-date synthesis of the evidence for risk factor exposure and the attributable burden of disease. By providing national and subnational assessments spanning the past 25 years,…
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine · 2019 · 6,422 citations
BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal…
Metadata from OpenAlex (CC0).